SQZ News and Press, SQZ Biotechnologies Company From 03/22/23

2023-03-22 17:04:33 ET SQZ Biotechnologies press release ( NYSE: SQZ ): FY GAAP EPS of -$2.76 beats by $0.34 . Revenue of $21.48M (-20.7% Y/Y) beats by $6.84M . As of December 31, 2022, the Company had cash and cash equivalents of $63.7 million and anticipates ...

A confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial Following review and recommendation by the Study Safety Committee, the Company is advancing SQZ-AAC-HPV-101 trial to the highest-dose cohort Stro...

Strategically Focused Company Structure to Prioritize Clinical Development and Deliver Critical, Clinical-Stage Data SQZ ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023 Phase 1 SQZ-AAC-HPV-101 Clinical Trial ...

2023-03-17 07:31:06 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biggest pre-market stock movers for Friday are ready to go as we dive into the latest news this morning! News moving stocks today include an asset sale, patent news, and more. Let&#...

HOUSTON, March 06, 2023 (GLOBE NEWSWIRE) -- SEACOR Marine Holdings Inc. (NYSE: SMHI) (the “Company” or “SEACOR Marine”), a leading provider of marine and support transportation services to offshore energy facilities worldwide, today announced results for its fourth qua...

SQZ Biotechnologies (NYSE: SQZ) today announced that on January 18, 2023, it received notice from the New York Stock Exchange (NYSE) indicating that the Company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s ...

Designation Represents Potential to Bring Important New Therapy to Patients Earlier Stable Disease Observed in Two Out of Four Evaluable Patients in eAPC Phase 1/2 Trial Including a Pronounced Pharmacodynamic Response in a Patient with Prolonged Stable Disease Interim Results from...

Strategic Reprioritization of Portfolio: Focus on Advancing Second-Generation Cell Therapy Program, Enhanced Antigen Presenting Cells Howard Bernstein, MD, PhD, Former Chief Scientific Officer, Appointed as Interim Chief Executive Office; Armon Sharei, PhD, to step down from role as CEO a...

Cell Squeeze ® Platform Offers Advantages for GMP Engineering of Multiple Cell Types and Reduced Manufacturing Time and Cost through its Point-of-Care System mRNA Constructs Encoding Multiple Linked Antigens Could Allow for a Multiantigen-Specific CD8+ T Cell Response S...

SQZ Biotechnologies press release ( NYSE: SQZ ): Q3 GAAP EPS of -$0.77 beats by $0.06 . Revenue of $3.5M (-27.1% Y/Y) misses by $0.76M . Company had cash and cash equivalents of $84.2 million and anticipates this will be sufficient to fund operating expenses an...